From b7279f3b01ec0237362ca74adc90ebdb832f7b97 Mon Sep 17 00:00:00 2001
From: FMS <fms@mbp14.local>
Date: Mon, 29 Apr 2024 11:28:40 +0200
Subject: [PATCH] Auto saved by Logseq

---
 assets/9789240000315-eng_1714380636887_0.edn  | 42 ++++++++++++++++++-
 .../hls__9789240000315-eng_1714380636887_0.md | 12 +++++-
 2 files changed, 52 insertions(+), 2 deletions(-)

diff --git a/assets/9789240000315-eng_1714380636887_0.edn b/assets/9789240000315-eng_1714380636887_0.edn
index 942697cd..9b8f1ab2 100644
--- a/assets/9789240000315-eng_1714380636887_0.edn
+++ b/assets/9789240000315-eng_1714380636887_0.edn
@@ -174,5 +174,45 @@
                                    :height 1403.1500999999998}),
                           :page 6},
                :content {:text "The group stressed the need to identify attainable targets that will:ƒ maintain the achievements obtained by on-going STH control programmes in the first decade;ƒ further expand the benefit to other groups at risk (i.e. WRA);ƒ promote the control of strongyloidiasis within STH control programmes, where warranted;ƒ align with the targets of other NTDs and with the Sustainable Development Goals(SDGs);ƒ take advantage of recent changes in the public health landscape reflecting the increased visibility of NTDs in the health arena; the familiarity of endemic countries with the principles of PC; and the engagement of pharmaceutical donors in covering the drug needs of additional groups at risk;ƒ highlight collaboration with WASH experts to reduce re-infection and the need for PC; andƒ progressively promote sustainability of the STH control programmes by endemic countries by adapting the intervention to the new epidemiological situation resulting from the successful implementation of the control measures (see Figure 2)."},
+               :properties {:color "yellow"}}
+              {:id #uuid "662f680f-a77b-46a0-8742-5189721a5257",
+               :page 9,
+               :position {:bounding {:x1 277.89217376708984,
+                                     :y1 760.5555973052979,
+                                     :x2 889.5338668823242,
+                                     :y2 813.1882877349854,
+                                     :width 992.1250999999999,
+                                     :height 1403.1500999999998},
+                          :rects ({:x1 299.1592330932617,
+                                   :y1 760.5555973052979,
+                                   :x2 859.1937789916992,
+                                   :y2 779.7258853912354,
+                                   :width 992.1250999999999,
+                                   :height 1403.1500999999998}
+                                  {:x1 277.89217376708984,
+                                   :y1 794.0179996490479,
+                                   :x2 889.5338668823242,
+                                   :y2 813.1882877349854,
+                                   :width 992.1250999999999,
+                                   :height 1403.1500999999998}),
+                          :page 9},
+               :content {:text "SAC: donations available since 2010 and continued until 2020 (albendazole).ƒ PreSAC: donations available since 2019 and continued until 2020 (mebendazole)"},
+               :properties {:color "yellow"}}
+              {:id #uuid "662f6816-25f8-4aa4-846a-266513ae9761",
+               :page 9,
+               :position {:bounding {:x1 299.1592330932617,
+                                     :y1 860.9856510162354,
+                                     :x2 857.3362350463867,
+                                     :y2 880.1559391021729,
+                                     :width 992.1250999999999,
+                                     :height 1403.1500999999998},
+                          :rects ({:x1 299.1592330932617,
+                                   :y1 860.9856510162354,
+                                   :x2 857.3362350463867,
+                                   :y2 880.1559391021729,
+                                   :width 992.1250999999999,
+                                   :height 1403.1500999999998}),
+                          :page 9},
+               :content {:text "No ivermectin donation for STH or prequalified generic ivermectin available"},
                :properties {:color "yellow"}}],
- :extra {:page 9}}
+ :extra {:page 10}}
diff --git a/pages/hls__9789240000315-eng_1714380636887_0.md b/pages/hls__9789240000315-eng_1714380636887_0.md
index c9f07a6f..d7c518a7 100644
--- a/pages/hls__9789240000315-eng_1714380636887_0.md
+++ b/pages/hls__9789240000315-eng_1714380636887_0.md
@@ -15,4 +15,14 @@ file-path:: ../assets/9789240000315-eng_1714380636887_0.pdf
   ls-type:: annotation
   hl-page:: 6
   hl-color:: yellow
-  id:: 662f6122-4efb-493d-a237-a4abaab4143a
\ No newline at end of file
+  id:: 662f6122-4efb-493d-a237-a4abaab4143a
+- SAC: donations available since 2010 and continued until 2020 (albendazole).ƒ PreSAC: donations available since 2019 and continued until 2020 (mebendazole)
+  ls-type:: annotation
+  hl-page:: 9
+  hl-color:: yellow
+  id:: 662f680f-a77b-46a0-8742-5189721a5257
+- No ivermectin donation for STH or prequalified generic ivermectin available
+  ls-type:: annotation
+  hl-page:: 9
+  hl-color:: yellow
+  id:: 662f6816-25f8-4aa4-846a-266513ae9761
\ No newline at end of file